Sample-to-result molecular diagnostic platforms and their suitability for infectious disease testing in low- and middle-income countries.

For S2R platforms to be suitable for implementation in LMIC some modifications by the manufacturers could be considered. Furthermore, strengthening health systems and digitalization are vital; as are smaller, cheaper, faster, and sustainable technologies.